@article{3034379,
    title = "Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek
Patients with Inflammatory Bowel Disease",
    author = "Orfanoudaki, Eleni and Zacharopoulou, Eirini and Kitsou, Vassiliki and and Karmiris, Konstantinos and Theodoropoulou, Angeliki and Mantzaris, and Gerassimos J. and Tzouvala, Maria and Michopoulos, Spyridon and Zampeli, and Evanthia and Michalopoulos, Georgios and Karatzas, Pantelis and Viazis, and Nikos and Liatsos, Christos and Bamias, Giorgos and Koutroubakis, and Ioannis E. and Hellen Grp Study IBD",
    journal = "Journal of Clinical Medicine Research",
    year = "2022",
    volume = "11",
    number = "3",
    publisher = "MDPI",
    issn = "1918-3003, 1918-3011",
    doi = "10.3390/jcm11030641",
    keywords = "COVID-19; Crohn's disease; vaccine; ulcerative colitis",
    abstract = "Since inflammatory bowel disease (IBD) patients were excluded from
vaccine authorization studies, limited knowledge exists regarding
perceptions and unfavorable effects of COVID-19 vaccination in this
group. We aimed to investigate the real-world use and adverse events
(AEs) of COVID-19 vaccines in Greek IBD patients. Fully vaccinated IBD
patients followed in Greek centers were invited to participate. All
patients filled out an anonymous online survey concerning the
vaccination program, which included information regarding demographics,
clinical characteristics, treatment, vaccination perceptions and
potential AEs. Overall, 1007 IBD patients were included. Vaccine
hesitancy was reported by 49%. Total AEs to vaccination were reported
by 81% after dose 1 (D1) and 76% after dose 2 (D2), including isolated
injection site reactions (36% and 24% respectively). Systemic AEs were
more common after D2 (51%, D2 vs. 44%, D1, p < 0.0001). Very few
patients reported new onset abdominal symptoms (abdominal pain 4% (D1),
6% (D2) and diarrhea 5% (D1), 7% (D2)). There were no serious AEs
leading to emergency room visit or hospitalization. In multivariate
analysis, AEs occurrence was positively associated with young age and
female gender (p < 0.0005 for both doses), whereas inactive disease was
negatively associated with AE in D1 (p = 0.044). SARS-CoV-2 vaccination
in Greek IBD patients demonstrated a favorable and reassuring safety
profile."
}